-
Real Time Chart
-
Stock Profile
-
Stock Fundamentals
Financials As Reported
- accession Number 0001682852-23-000021
- accounts Payable Current 389,000,000
- accounts Receivable Net Current 1,113,000,000
- accumulated Other Comprehensive Income Loss Net Of Tax --267,000,000
- allocated Share Based Compensation Expense 75,000,000
- amendment Flag false
- assets 24,125,000,000
- assets Current 12,122,000,000
- available For Sale Securities Debt Maturities Single Maturity Date 1970-05-30
- cash And Cash Equivalents At Carrying Value 3,441,000,000
- cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 3,461,000,000
- cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect 244,000,000
- cik 1,682,852
- city Area Code 617
- common Stock Par Or Stated Value Per Share 0.0001
- common Stock Shares Authorized 1,600,000,000
- common Stock Shares Issued 384,000,000
- common Stock Shares Outstanding 384,000,000
- comprehensive Income Net Of Tax 182,000,000
- contract With Customer Liability 1,892,000,000
- contract With Customer Liability Current 1,219,000,000
- cost Of Goods And Services Sold 792,000,000
- current Fiscal Year End Date --12-31
- date Filed 2023-05-04
- depreciation Depletion And Amortization 78,000,000
- document Fiscal Period Focus Q1
- document Fiscal Year Focus 2,023
- document Period End Date 2023-03-31
- document Transition Report false
- document Type 10-Q
- earnings Per Share Basic 0.2
- earnings Per Share Diluted 0.19
- effective Income Tax Rate Continuing Operations 1.259
- employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized 789,000,000
- employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition 1 P3Y2M12D
- entity Address Address Line 1 200 Technology Square
- entity Address City Or Town Cambridge,
- entity Address Postal Zip Code 2,139
- entity Address State Or Province MA
- entity Central Index Key 1,682,852
- entity Current Reporting Status Yes
- entity Emerging Growth Company false
- entity File Number 001-38753
- entity Filer Category Large Accelerated Filer
- entity Incorporation State Country Code DE
- entity Interactive Data Current Yes
- entity Name Moderna, Inc.
- entity Registrant Name Moderna, Inc.
- entity Shell Company false
- entity Small Business false
- entity Tax Identification Number 81-3467528
- finance Lease Liability 984,000,000
- finance Lease Liability Current 153,000,000
- finance Lease Liability Current Statement Of Financial Position Extensible List http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
- finance Lease Liability Noncurrent 831,000,000
- finance Lease Liability Payments Due 1,637,000,000
- finance Lease Liability Payments Due Next Twelve Months 128,000,000
- finance Lease Liability Payments Due Year Four 23,000,000
- finance Lease Liability Payments Due Year Three 107,000,000
- finance Lease Liability Payments Due Year Two 128,000,000
- finance Lease Liability Undiscounted Excess Amount 653,000,000
- finance Lease Right Of Use Asset 1,033,000,000
- income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest --305,000,000
- income Tax Expense Benefit --384,000,000
- increase Decrease In Accounts Payable --117,000,000
- increase Decrease In Accounts Receivable --272,000,000
- increase Decrease In Contract With Customer Liability --819,000,000
- increase Decrease In Inventories --216,000,000
- increase Decrease In Other Operating Liabilities --15,000,000
- inventory Net 732,000,000
- irs Number 813,467,528
- lessee Operating Lease Liability Payments Due 159,000,000
- lessee Operating Lease Liability Payments Due Next Twelve Months 23,000,000
- lessee Operating Lease Liability Payments Due Year Four 19,000,000
- lessee Operating Lease Liability Payments Due Year Three 18,000,000
- lessee Operating Lease Liability Payments Due Year Two 20,000,000
- lessee Operating Lease Liability Undiscounted Excess Amount 35,000,000
- liabilities 5,262,000,000
- liabilities And Stockholders Equity 24,125,000,000
- liabilities Current 3,499,000,000
- local Phone Number 714-6500
- net Cash Provided By Used In Financing Activities --542,000,000
- net Cash Provided By Used In Investing Activities 2,011,000,000
- net Cash Provided By Used In Operating Activities --1,225,000,000
- net Income Loss 79,000,000
- operatingand Finance Lease Liability 1,108,000,000
- operatingand Finance Lease Rightof Use Asset 1,150,000,000
- operating Income Loss --366,000,000
- operating Lease Liability 124,000,000
- operating Lease Liability Current 28,000,000
- operating Lease Liability Current Statement Of Financial Position Extensible List http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
- operating Lease Liability Noncurrent 96,000,000
- operating Lease Right Of Use Asset 117,000,000
- other Assets Current 64,000,000
- other Assets Noncurrent 1,164,000,000
- other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent 103,000,000
- other Comprehensive Income Loss Reclassification Adjustment From AOCI For Sale Of Securities Net Of Tax --16,000,000
- other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax 79,000,000
- other Liabilities Current 212,000,000
- other Liabilities Noncurrent 163,000,000
- other Noncash Income Expense 4,000,000
- other Nonoperating Income Expense --48,000,000
- payments For Repurchase Of Common Stock 526,000,000
- payments To Acquire Available For Sale Securities Debt 1,085,000,000
- payments To Acquire Businesses Net Of Cash Acquired 85,000,000
- payments To Acquire Property Plant And Equipment 113,000,000
- period End 1,680,220,800,000
- period Start 1,672,531,200,000
- proceeds From Maturities Prepayments And Calls Of Available For Sale Securities 1,360,000,000
- proceeds From Sale Of Available For Sale Securities Debt 1,957,000,000
- report Link https://www.sec.gov/Archives/edgar/data/1682852/000168285223000021/mrna-20230331_htm.xml
- research And Development Expense 1,131,000,000
- retained Earnings Accumulated Deficit 18,399,000,000
- share Based Compensation 75,000,000
- stockholders Equity 18,863,000,000
- trading Symbol MRNA
- update 1970-01-01
- weighted Average Number Diluted Shares Outstanding Adjustment 19,000,000
- weighted Average Number Of Diluted Shares Outstanding 405,000,000
- weighted Average Number Of Shares Outstanding Basic 386,000,000
- id REPORTED_FINANCIALS
- key MRNA
- subkey 10-Q
- date 2023-05-04
- updated 2023-05-05
-
Symbol Info
-
Symbol Over View
-
Technical Analysis